Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multi- Center Study to Assess the Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy

NCT05059223 is registered in ClinicalTrials.gov with Axsome Therapeutics, Inc. as lead sponsor.

NCT NCT05059223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05059223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multi- Center Study to Assess the Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy
Lead sponsor
Axsome Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 15, 2021
Completion date
March 15, 2024
Enrollment
90 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

cataplexy, excessive daytime sleepiness, narcolepsy